Related references
Note: Only part of the references are listed.The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation
Christian U. Blank
CURRENT OPINION IN ONCOLOGY (2014)
FcγRI™I™B controls the potency of agonistic anti-TNFR mAbs
Ann L. White et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Aurelien Marabelle et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Fc gamma receptors enable anticancer action of proapoptotic and immune-modulatory antibodies
Jeong M. Kim et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
Yannick Bulliard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Pancreatic Islet Xenograft Survival in Mice Is Extended by a Combination of Alpha-1-Antitrypsin and Single-Dose Anti-CD4/CD8 Therapy
Efrat Ashkenazi et al.
PLOS ONE (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Modulation of GITR for cancer immunotherapy
David A. Schaer et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype
Daniel Hirschhorn-Cymerman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
CD8+ T Cells: GITR Matters
Simona Ronchetti et al.
SCIENTIFIC WORLD JOURNAL (2012)
An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
Nicholas S. Wilson et al.
CANCER CELL (2011)
Science gone translational: the OX40 agonist story
Andrew D. Weinberg et al.
IMMUNOLOGICAL REVIEWS (2011)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies
Fubin Li et al.
SCIENCE (2011)
Signaling Through OX40 Enhances Antitumor Immunity
Shawn M. Jensen et al.
SEMINARS IN ONCOLOGY (2010)
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
Daniel Hirschhorn-Cymerman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
Sergio A. Quezada et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
Silvia Piconese et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models
Rebecca E. Sadun et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Fc gamma receptors as regulators of immune responses
Falk Nimmerjahn et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Glucocorticoid-induced TNFR-Related protein lowers the threshold of CD28 costimulation in CD8+ T cells
Simona Ronchetti et al.
JOURNAL OF IMMUNOLOGY (2007)
The crystal structure of the costimulatory OX40-OX40L complex
Deanne M. Compaan et al.
STRUCTURE (2006)
Fc gamma receptors: Old friends and new family members
F Nimmerjahn et al.
IMMUNITY (2006)
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells
K Ko et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells
MJ Turk et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells
F Kanamaru et al.
JOURNAL OF IMMUNOLOGY (2004)
Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40
K Sugamura et al.
NATURE REVIEWS IMMUNOLOGY (2004)
Engagement of the OX-40 receptor in vivo enhances antitumor immunity
AD Weinberg et al.
JOURNAL OF IMMUNOLOGY (2000)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)